CRISPR セラピューティクス AG
CH ˙ BRSE
SecurityCH:1CG / CRISPR Therapeutics AG
InstitutionHighTower Advisors, LLC
Latest Disclosed Ownership25,004 shares
Latest Disclosed Value $ 1,189,440
HighTower Advisors, LLC ownership in 1CG / CRISPR Therapeutics AG

On May 5, 2026 - HighTower Advisors, LLC filed a 13F-HR form disclosing ownership of 25,004 shares of CRISPR Therapeutics AG (CH:1CG) valued at $1,189,440 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 27,509 shares of CRISPR Therapeutics AG. This represents a change in shares of -9.11% during the quarter.

HighTower Advisors, LLC has a history of taking positions in derivatives of the underlying security (1CG) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CH:1CG / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 25,004 -2,505 -9.11 1,189 -17.55 0.0013
2026-02-06 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 27,509 783 2.93 1,443 -16.74 0.0016
2025-11-07 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 26,726 -22,470 -45.67 1,732 -27.59 0.0020
2025-08-11 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 49,196 16,163 48.93 2,393 112.81 0.0030
2025-05-13 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 33,033 1,325 4.18 1,124 -9.94 0.0015
2025-02-07 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 31,708 -6,608 -17.25 1,248 -30.32 0.0017
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 38,316 -1,349 -3.40 1,791 -16.54 0.0026
2024-08-13 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 39,665 -2,908 -6.83 2,146 -25.90 0.0033
2024-05-06 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 42,573 5,043 13.44 2,896 22.71 0.0047
2024-02-12 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 37,530 -2,465 -6.16 2,360 30.24 0.0040
2023-11-08 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 39,995 -36 -0.09 1,812 -19.47 0.0034
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 40,031 -228 -0.57 2,250 23.49 0.0044
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 40,259 9,747 31.94 1,822 48.01 0.0040
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 30,512 -4,898 -13.83 1,231 -46.94 0.0028
2022-11-09 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 35,410 1,421 4.18 2,320 12.57 0.0062
2022-08-10 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 33,989 -15,894 -31.86 2,061 -34.13 0.0053
2022-05-12 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 49,883 16,494 49.40 3,129 23.04 0.0070
2022-02-10 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 33,389 -9,770 -22.64 2,543 -47.35 0.0056
2021-11-12 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 43,159 3,006 7.49 4,830 -25.61 0.0129
2021-08-06 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 40,153 10,668 36.18 6,493 81.22 0.0188
2021-05-10 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 29,485 3,014 11.39 3,583 -11.60 0.0113
2021-02-10 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 26,471 1,497 5.99 4,053 94.20 0.0169
2020-11-13 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,974 -385 -1.52 2,087 12.14 0.0101
2020-08-10 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 25,359 4,809 23.40 1,861 113.17 0.0102
2020-05-21 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,550 1,850 9.89 873 -22.95 0.0057
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 18,700 1,075 6.10 1,133 56.93 0.0067
2019-11-12 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 17,625 -5,043 -22.25 722 -32.40 0.0039
2019-08-13 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 22,668 2,523 12.52 1,068 48.13 0.0064
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,145 3,453 20.69 721 50.21 0.0048
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 16,692 -7,669 -31.48 480 -55.43 0.0037
2018-11-09 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,361 4,920 25.31 1,077 -5.77 0.0078
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 19,441 19,441 1,143 0.0090
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-07 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-11 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 15,000 50.00 6 50.00 n/a n/a n/a
2025-05-13 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 4 n/a n/a n/a
2021-11-12 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-08-06 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 100 5 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-05-11 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-10 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 2 1 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.